Follow-up Avastin shown to advantage colon cancer patients

<p>CHICAGO (Reuters) – <span>Colorectal cancer patients</span> treated with a follow-up turn of Avastin transport improved than those given <span>chemotherapy</span> alone after their illness has worsened, according to formula of a vast clinical trial.</p>
<p> Avastin, sole by Roche, is authorized as a first-line or second-line diagnosis for <span>colorectal cancer</span>, though not for both. Sales of a drug, also famous as bevacizumab, totaled $5.3 billion Swiss francs ($5.5 billion) final year.</p>
<p> “By simply switching <span>chemotherapy drugs</span> when a cancer progresses and stability with bevacizumab, we can make second-line diagnosis even some-more powerful,” pronounced Dr. <span>Dirk Arnold</span>, executive of Germany’s <span>Hubertus Wald Tumor Center of University Cancer Center Hamburg</span>, and a hearing investigator.</p>
<p> ...